EON

Blood Platelet Booster Gets FDA Approval

Washington, D.C.- The blood platelet drug Nplate has been declared effective and safe for the treatment of a rare clotting disorder that has as a side effect uncontrollable bleeding.

The Food and Drug Administration said last Friday that they have examined the Amgen blood product and found that it is safe and now approved for usage and sale in the United States.

It is a drug that is injectable and it helps cause the blood marrow to produce blood platelets in patients that have the rare condition chronic immune thrombocytopenic purpura , or ITP disease.

According to the FDA the drug is approved for prescription for those patients that cannot be helped by anything else, and should be considered a drug of last choice by doctors for their patients.

It is an important drug, but it should be used with caution based on the FDA approval.

The other treatments that are commonly used for ITP include the usage of immune suppressing drugs, surgery to remove the spleen, or the use of steroids.

The cost using the Nplate treatment program is expected to be less or the same as other types of standard ITP disease treatments.

After two different studies involving 125 different patients that took Nplate for six months, and a group that took a placebo, the FDA then approved the usage of the drug.

Those physicians that want to be able to prescribe Nplate are required to register themselves professionally and their patients on Nplate into a FDA registry that will track patients to make sure their long term health is being safeguarded.